lasmiditan (Reyvow) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
LASMIDITAN is a serotonin (5-HT) receptor agonist without vasoconstrictor activity, which selectively binds to the 5-HT(1F) receptor subtype. It is under development for the treatment of migraine.   NCATS

Chemistry

  • SMILES: CN1CCC(CC1)C(=O)C2=CC=CC(NC(=O)C3=C(F)C=C(F)C=C3F)=N2
  • InChIKey: XEDHVZKDSYZQBF-UHFFFAOYSA-N
  • Mol. Mass: 377.3603
  • ALogP: 3.28
  • ChEMBL Molecule:
    lasmiditan  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$59.7075 - $80.9424
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2,4,6-trifluoro-n-(6-((1-methylpiperidin-4-yl)carbonyl)pyridin-2yl)benzamide | col-144 | las106521 | lasmiditan | lasmiditan hydrochloride | ly573144 | ly-573144

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (1)


 

Migraine Disorders (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Healthy Volunteers (Phase 1)

Keratosis, Actinic (Phase 3)

Migraine Disorders (Phase 3)

Recreational Drug Use (Phase 1)

Substance Abuse, Oral (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 33
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue